Marshall Wace’s Briacell Therapeutics BCTX Stock Holding History

Marshall Wace’s Portfolio BCTX Stock Details BCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-422	Closed	-$337K	–	3024
2021 Q2	$337K	Buy	+422	New	+$263K	﹤0.01%	2285

Other funds holding BCTX

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

STA

Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

AWM

Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

FIM

Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return

Belvedere Trading Chicago, Illinois $84.4B AUM 52.68% 1-Year Est. Return

Marshall Wace's BCTX Position: Q3 2021 in Review

Marshall Wace sold out of Briacell Therapeutics (BCTX) in Q3 2021, closing a stake of 422 shares — an estimated $337K sold.

Marshall Wace first reported a position in BCTX in Q2 2021 and held it in 1 quarter. The position peaked at $337K in Q2 2021. 19 funds tracked by Wall St. Rank hold BCTX as of Q3 2021.

Marshall Wace reported no remaining Briacell Therapeutics position as of Q3 2021 after selling out during the quarter.
Marshall Wace sold 422 Briacell Therapeutics shares in Q3 2021, an estimated $337K.
Marshall Wace first reported a position in Briacell Therapeutics in Q2 2021 and held it in 1 quarter.
Marshall Wace's Briacell Therapeutics position peaked at $337K in Q2 2021.
19 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q3 2021.

Based on Marshall Wace's 13F filing for Q3 2021, filed 15 Nov 2021.